Kirsten Drejer

Kirsten joined the Board of Malin as Independent Non-Executive Director in March 2020.

Kirsten founded and served as CEO of Symphogen, a Danish private biopharmaceutical company, and has extensive board experience on both private and public companies across the life sciences sector, including Zealand Pharma, where she currently serves as vice-chairman of the board, Bioporto and Alligator Bioscience. She was previously a member of the boards of The Danish National Advanced Technology Foundation and The Danish Growth Fund. A graduate of the Danish University of Pharmaceutical Sciences, Kirsten has an MSc in Pharmacy and a PhD in Pharmacology.